Welireg, as the first approved HIF-2 α inhibitor for the treatment of VHL syndrome associated renal cell carcinoma, has shown significant tumor control efficacy and manageable safety features in clinical trials. This drug exerts therapeutic effects by targeting the hypoxia inducible factor pathway, providing a new treatment option for VHL patients.

1. Clinical efficacy data of Welireg

(1) Objective response rate: In the critical phase II study, the objective response rate of bevacizumab in the treatment of VHL related renal cell carcinoma was close to half, and the median duration of response was not achieved.

(2) Disease control rate: Most patients achieve disease control (complete remission+partial remission+disease stability), significantly delaying tumor progression.

(3) Progression free survival: The median progression free survival is 24 months, which is better than traditional treatment options.

2. Advantages of the mechanism of action of Welireg

(1) Targeted therapy: Specific inhibition of HIF-2 α, blocking abnormal angiogenesis and tumor growth signaling pathways caused by VHL gene deletion.

(2) Accuracy: Targeting VHL gene mutation characteristics, reducing the impact on normal tissues, and improving treatment specificity.

3. Treatment characteristics of Welireg

(1) Oral convenience: The once daily dosing regimen improves patient compliance and is suitable for long-term disease management.

(2) Multi lesion control: It has shown therapeutic effects on multiple lesions such as renal cell carcinoma and pancreatic neuroendocrine tumors associated with VHL syndrome.

4. Safety characteristics of Welireg

(1) The main adverse reactions are anemia, fatigue, etc., most of which are grade 1-2, and can be effectively managed through dosage adjustment.

(2) Regular monitoring of hemoglobin and blood oxygen saturation is necessary to promptly address symptoms related to anemia and hypoxia.